公开(公告)号：US12115214B2

公开(公告)日：2024-10-15

申请号：US16685424

申请日：2019-11-15

申请人： Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V

发明人： Rikard Holmdahl ,  Jan Kihlberg ,  Balik Dzhambazov ,  Mikael Vestberg

IPC分类号： A61K39/00 ,  A61K47/64 ,  A61K47/68 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18

CPC分类号： A61K39/0008 ,  A61K47/6425 ,  A61K47/6811 ,  A61K47/6843 ,  C07K7/08 ,  C07K14/4713 ,  C07K14/705 ,  C07K16/18 ,  A61K2039/605 ,  A61K2039/6056 ,  C07K2319/33

摘要： The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type II collagen such as peptides having at least the sequence AGFKGEA, or IAGFKGEQPKG, or the peptide AAAKAAA. Preferably a hydroxylysine in the peptides are glycosylated.

公开(公告)号：US20240173391A1

公开(公告)日：2024-05-30

申请号：US18552383

申请日：2022-03-25

申请人： Nykode Therapeutics ASA ,  Genentech Inc.

发明人： Agnete Øvre Fredriksen ,  Karoline Schjetne ,  Stine Granum ,  Audun Trygge Haugen Bersaas ,  Ina Park Rhee ,  Siri Brinchmann-Hansen Torhaug

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K39/0011 ,  A61K39/39541 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/6056 ,  A61K2039/627

摘要： This invention relates to methods and kits for treating a subject having cancer, e.g. a patient, by administering to the subject an anticancer vaccine in combination with one or more checkpoint inhibitors.

公开(公告)号：US20240067700A1

公开(公告)日：2024-02-29

申请号：US18234640

申请日：2023-08-16

申请人： Cue Biopharma, Inc.

发明人： Ronald D. Seidel, III ,  Rodolfo J. Chaparro ,  John F. Ross ,  Saso Cemerski

IPC分类号： C07K14/74 ,  A61K39/00 ,  C07K14/47 ,  C07K14/55

CPC分类号： C07K14/70539 ,  A61K39/001164 ,  C07K14/47 ,  C07K14/55 ,  A61K2039/55533 ,  A61K2039/605 ,  A61K2039/6056 ,  A61K2039/627 ,  C07K2319/30

摘要： The present disclosure provides T-cell modulatory polypeptides (TMPs) that comprise a MOD, class I HLA polypeptides (a class I HLA heavy chain polypeptide and a β2 microglobulin polypeptide), and a KRAS peptide (e.g., a KRAS peptide comprising a cancer-associated mutation) that presents an epitope to a T-cell receptor. A TMP is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

公开(公告)号：US20240066118A1

公开(公告)日：2024-02-29

申请号：US18260858

申请日：2022-01-12

申请人： Cornell University

发明人： Julie Magarian BLANDER

IPC分类号： A61K39/39 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04

CPC分类号： A61K39/39 ,  A61K39/001188 ,  A61P35/00 ,  A61P37/04 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/572 ,  A61K2039/6056 ,  A61K2039/6068

摘要： Provided are compositions and methods that relate to Inflammasome Agonist Proteins (IAPS) that are used to stimulate immune responses. IAPS are used with Toll-Like Receptor (TLR) ligands, antigens, cell surface binding proteins, and binding partners that direct to IAPs or fusion proteins containing the IAP to a particular target. The IAP constructs can be used directly to stimulate immune responses, or in conjunction with other components such as antigens, whereby the IAPs function as adjuvants.

公开(公告)号：US20230145060A1

公开(公告)日：2023-05-11

申请号：US17631588

申请日：2020-07-31

申请人： The Hospital for Sick Children ,  The Governing Council of the University of Toronto

发明人： Jean-Philippe Julien ,  Edurne Rujas Diez ,  Bebhinn Treanor ,  Tiantian Zhao

IPC分类号： A61K39/21 ,  A61K47/64 ,  A61K47/68 ,  A61K39/385 ,  A61K49/00 ,  A61P31/18 ,  C12P21/02

CPC分类号： A61K39/21 ,  A61K47/64 ,  A61K47/6803 ,  A61K39/385 ,  A61K49/0002 ,  A61P31/18 ,  C12P21/02 ,  A61K2039/6056

摘要： A fusion protein comprises a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety linked to the first nanocage monomer subunit; wherein the fusion protein self-assembles with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.

公开(公告)号：US20190216910A1

公开(公告)日：2019-07-18

申请号：US16263098

申请日：2019-01-31

申请人： President and Fellows of Harvard College

发明人： David J. Mooney ,  W. Aileen Li ,  Omar Abdel-Rahman Ali ,  Ting-Yu Shih

IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K47/02 ,  A61K47/34

CPC分类号： A61K39/001106 ,  A61K9/0019 ,  A61K9/5031 ,  A61K39/00119 ,  A61K39/39 ,  A61K47/02 ,  A61K47/34 ,  A61K2039/5154 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55522 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/6056 ,  A61K2039/812 ,  A61K2039/876 ,  A61P35/00

摘要： The provided herein are methods and compositions for eliciting an immune response to an antigen, such as cancer and microbial antigens.

公开(公告)号：US20190184008A1

公开(公告)日：2019-06-20

申请号：US16141157

申请日：2018-09-25

申请人： INSERM (Institut National de la Santé et de la Recherche Mêdicale ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

发明人： Yves Levy ,  Gerard Zurawski ,  Sandra Zurawski ,  Anne-Laure Flamar

IPC分类号： A61K39/21 ,  C07K16/28 ,  A61P31/18 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K2039/505 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6056 ,  A61K2039/627 ,  A61P31/18 ,  C07K14/005 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2319/02 ,  C07K2319/40 ,  C12N7/00 ,  C12N2740/16134 ,  C12N2740/16171

摘要： Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

公开(公告)号：US09950049B2

公开(公告)日：2018-04-24

申请号：US15154273

申请日：2016-05-13

申请人： ERYTECH PHARMA

发明人： Yann Godfrin ,  Alice Banz

IPC分类号： A61K35/28 ,  A61K35/26 ,  C12N5/00 ,  A61K38/00 ,  A61K39/00 ,  A61K35/18 ,  A61K47/02 ,  A61K47/22 ,  A61K47/26 ,  C07K16/28

CPC分类号： A61K39/0011 ,  A61K35/18 ,  A61K47/02 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/6056 ,  C07K16/2806 ,  A61K2300/00

摘要： The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumor cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumor vaccine containing such a composition.

公开(公告)号：US20180100011A1

公开(公告)日：2018-04-12

申请号：US15820310

申请日：2017-11-21

申请人： École Polytechnique Fédérale de Lausanne (EPFL)

发明人： Jeffrey A. Hubbell ,  Stephan Kontos ,  Karen Y. Dane

IPC分类号： C07K16/18 ,  C12N9/82 ,  A61K39/00 ,  C07K7/08 ,  C07K14/62 ,  C07K14/74 ,  C07K16/28 ,  A61K9/51 ,  A61K9/107 ,  A61K38/00

CPC分类号： C07K16/18 ,  A61K9/1075 ,  A61K9/513 ,  A61K38/00 ,  A61K39/0008 ,  A61K39/001 ,  A61K47/60 ,  A61K47/62 ,  A61K47/64 ,  A61K47/646 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6901 ,  A61K2039/505 ,  A61K2039/6031 ,  A61K2039/6056 ,  A61K2039/627 ,  C07K7/08 ,  C07K14/62 ,  C07K14/70539 ,  C07K16/2896 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/23 ,  C07K2319/33 ,  C07K2319/41 ,  C07K2319/43 ,  C07K2319/74 ,  C12N9/82 ,  C12Y305/01001

摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

公开(公告)号：US20180028630A1

公开(公告)日：2018-02-01

申请号：US15664065

申请日：2017-07-31

申请人： Lan Bo Chen

发明人： Lan Bo Chen

IPC分类号： A61K39/00 ,  A61K39/39 ,  C07K14/705

CPC分类号： A61K39/0011 ,  A61K39/39 ,  A61K47/6415 ,  A61K47/646 ,  A61K47/68 ,  A61K2039/55572 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6056 ,  A61K2039/62 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/705 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/74

摘要： An immunogenic composition that includes a glycoconjugate containing a fusion protein composed of an immunoglobulin gamma Fc domain fused to a tumor-associated antigen, the fusion protein being cross-linked to an azido-modified stage-specific embryonic antigen 4 conjugated to diphtheria toxoid cross-reactive material 197; and α-galactosylceramide C34 or α-glucosylceramide C34. Also provided are methods for treating cancer by administering the immunogenic composition to a patient.